XML 27 R16.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Goodwill and Intangible Assets, Net | 9 Months Ended
--- | ---
Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets, Net | Goodwill and Intangible Assets, Net Changes in the carrying amount of goodwill were as follows:
(In millions) | U.S. Pharmaceutical and Specialty Solutions |  | European Pharmaceutical Solutions |  | Medical-Surgical Solutions |  | Other |  | Total
Balance, March 31, 2018 | $ | 4,110 |  |  | $ | 1,850 |  |  | $ | 2,070 |  |  | $ | 2,894 |  |  | $ | 10,924 |
Goodwill acquired | — |  |  | 52 |  |  | 360 |  |  | 12 |  |  | 424 |
Goodwill impairment charges | — |  |  | (570 | ) |  | — |  |  | (21 | ) |  | (591 | )
Acquisition accounting, transfers and other adjustments | 13 |  |  | (4 | ) |  | 16 |  |  | 6 |  |  | 31 |
Foreign currency translation adjustments, net | (49 | ) |  | (135 | ) |  | — |  |  | (85 | ) |  | (269 | )
Balance, December 31, 2018 | $ | 4,074 |  |  | $ | 1,193 |  |  | $ | 2,446 |  |  | $ | 2,806 |  |  | $ | 10,519 |
As of December 31, 2018, accumulated goodwill impairment losses were $1,736 million and $452 million in our European Pharmaceutical Solutions segment and Other. As of March 31, 2018, accumulated goodwill impairment losses were $1,299 million and $456 million in our European Pharmaceutical segment and Other. Refer to Financial Note 3, “Goodwill Impairment Charges,” for more information on goodwill impairment charges. Information regarding intangible assets is as follows:
| December 31, 2018 |  | March 31, 2018
(Dollars in millions) | Weighted Average Remaining Amortization Period (years) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount
Customer relationships | 12 |  | $ | 3,980 |  |  | $ | (1,856 | ) |  | $ | 2,124 |  |  | $ | 3,619 |  |  | $ | (1,550 | ) |  | $ | 2,069 |
Service agreements | 11 |  | 1,011 |  |  | (414 | ) |  | 597 |  |  | 1,037 |  |  | (386 | ) |  | 651 |
Pharmacy licenses | 25 |  | 767 |  |  | (353 | ) |  | 414 |  |  | 684 |  |  | (196 | ) |  | 488 |
Trademarks and trade names | 13 |  | 884 |  |  | (233 | ) |  | 651 |  |  | 932 |  |  | (187 | ) |  | 745 |
Technology | 4 |  | 139 |  |  | (89 | ) |  | 50 |  |  | 147 |  |  | (84 | ) |  | 63 |
Other | 5 |  | 285 |  |  | (201 | ) |  | 84 |  |  | 262 |  |  | (176 | ) |  | 86 |
Total |  |  | $ | 7,066 |  |  | $ | (3,146 | ) |  | $ | 3,920 |  |  | $ | 6,681 |  |  | $ | (2,579 | ) |  | $ | 4,102 |
Amortization expense of intangible assets was $122 million and $365 million for the third quarter and nine months ended December 31, 2018 and $123 million and $370 million for the third quarter and nine months ended December 31, 2017. Estimated annual amortization expense of these assets is as follows: $112 million, $429 million, $412 million, $379 million and $274 million for the remainder of 2019 and each of the succeeding years through 2023 and $2,314 million thereafter. All intangible assets were subject to amortization as of December 31, 2018 and March 31, 2018. Refer to Financial Note 2, “Restructuring and Asset Impairment Charges,” for more information on intangible asset impairments recorded during the first quarter of 2019 for our U.K. retail business and the third quarter of 2019 for our Rexall Health retail business.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration